Patent · US Active

Drug carrier, brain-targeting nanodrug based on CRISPR gene editing technology and preparation method and use thereof

US12161700B2 · kind B2 · utility

0Cited by

0References

3Claims

0Family size

Assignee

Henan University · CN

Inventors

Weimin Ruan · Kaifeng, CN
Mingzhu Jiao · Kaifeng, CN
Bingyang Shi · Kaifeng, CN
Meng Zheng · Cambridge, US

Key dates

Filing date	Dec 4, 2020
Grant date	Dec 10, 2024
Priority date	—
Expiry date	Mar 24, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC08G2650/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides a drug carrier, a brain-targeting nanodrug based on CRISPR gene editing technology and a preparation method and use thereof. The nanodrug contains nanoparticles prepared by coupling Cas9/sgRNA and drug carriers. The drug carrier includes a polymer mPEG-P (GPMA, FPMA) and a polymer Ang-PEG-PGPMA, wherein a structural formula of the mPEG-P (GPMA, FPMA) is: a structural formula of the polymer Ang-PEG-PGPMA is: where n is 35-45, x1 is 15-20, y is 2-4, m is 75-85, and x2=x1. The guanidino group of the drug carrier can be combined with the ribonucleoprotein complex by electrostatic action, salt bridge formation, or hydrogen bonding action. Also provided are methods of suppressing and treating tumors at a gene level using the drug carrier to transport the therapeutic drug to the lesion site.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.